Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) dropped -2.34% and closed the trade at $ 1.25. The company recorded a trading capacity of 1.46 million shares above its three months average daily volume of 788.54 thousand shares. During the last trade, shares reached to high price of $1.30 and touched the low price of $1.21. The stock’s 50-day moving average is noted at $1.13 and its 200-day moving average is stands at $5.07.
Additionally, the companyhas EPS of -2.12. The company has market capitalization of $28.29M.
Currently Tokai Pharmaceuticals, Inc. (TKAI) captured an average recommendation of “ Hold ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “0″ Analysts”. “0” rated “Sell” for the company. “5” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $1.72 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $2.00 however minimum price target advised by analysts is $1.15. The Median price target for the stock is measured at $2.00.
Presently, Analysts decided consensus EPS estimate of $-0.43 for present quarter and one month ago projected EPS estimate was at $-0.45. If we take a look at back 3 month ago, consensus EPS estimate was $-0.48.
A current consensus EPS estimate for next quarter is at $-0.34 and 3 month ago EPS forecast was $-0.50. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.38.
For current fiscal year, most recent EPS estimate is set at $-1.81 based on Analyst consensus and three month ago consensus EPS opinions was at $-2.00. During period one month ago, consensus EPS forecast was decided at $-1.85.
A current consensus EPS projection for next fiscal year is observed at $-1.13 and one month ago consensus EPS forecast was at $-1.34. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-1.50 by analysts.
One Month ago, the stock has gained consensus mean rating of Hold based on the analysis of brokerage analyst firms polled. 0 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 5 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 7 said a “Buy Rating” and 0 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.